Intravenous (IV) infusion has been the standard for antibody drugs — it’s effective and controlled by nurses. But in India, where hospital beds are scarce and families often travel far for care, subcutaneous (SC) self‑injection is a game‑changer. The India antibodies market analysis shows that SC is the fastest‑growing route of administration, especially for chronic diseases like rheumatoid arthritis and psoriasis. Patients can be trained in 15 minutes, then inject themselves at home.

What’s holding SC back? Cost. Auto‑injector pens add $50‑$100 per dose, which is significant in a price‑sensitive market. Also, some patients are afraid of needles or have dexterity issues. The India antibodies market forecast predicts that IV will remain the largest segment for oncology (where high doses are needed), but SC will dominate for autoimmune and rare diseases.

Indian companies are now developing pre‑filled syringes without the expensive auto‑injector mechanism, bringing down costs. And they’re offering nurse‑led training programs to boost confidence.

The bottom line: choice is good. Patients should be able to pick the route that fits their life. And the market is finally providing options.